Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAPILLON: amivantamab plus carboplatin-pemetrexed versus carboplatin-pemetrexed in EGFR exon 20 insertion-mutated advanced non-small cell lung cancer
jRCT2051200087Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of amivantamab, carboplatin and pemetrexed in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-Free Survival (PFS). Started Feb 2021; status: active, not recruiting.
02
Drugs
amivantamabcarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051200087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200087.